Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

mRNA 2752

Next Previous
Drug Profile

mRNA 2752

Alternative Names: iTu triple combination - Moderna Therapeutics; mRNA intratumoral immuno-oncology therapeutics - Moderna Therapeutics; mRNA-2752; OX40L/IL-23/IL-36γ

Latest Information Update: 03 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Moderna Therapeutics
  • Class Antineoplastics; Immunotherapies; Interleukins; Lipids; Proteins; RNA
  • Mechanism of Action IL36G protein expression stimulants; Interleukin 23 expression stimulants; OX40 ligand expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Lymphoma; Malignant melanoma; Solid tumours

Most Recent Events

  • 03 Oct 2025 ModernaTX completes the phase I trials for Solid tumours, Lymphoma (Late stage disease, Combination therapy, Second line therapy or greater, Monotherapy) and Malignant melanoma (Neoadjuvant therapy, Combination therapy) in Australia, USA and Israel (NCT03739931)
  • 12 Sep 2024 Discontinued - Phase-0 for Breast cancer (Combination therapy) in USA (Intralesional)
  • 12 Sep 2024 Discontinued - Phase-I for Lymphoma (Combination therapy, Late-stage disease, Second-line therapy or greater) in Australia, Israel, USA (Intratumoural)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top